Studies have indicated that bosutinib, a Src/c-Abl inhibitor, enhances autophagy and reduces the accumulation of misfolded proteins, such as mutant SOD1, which are implicated in ALS pathology [46]. This evidence concerns the gene ABL1 and amyotrophic lateral sclerosis.